Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Dec;1(6):574-81.
doi: 10.1016/j.coviro.2011.08.006. Epub 2011 Oct 1.

Fitness of neuraminidase inhibitor-resistant influenza A viruses

Tatiana Baranovich  1 , Robert G Webster, Elena A Govorkova
Affiliations
Review

Fitness of neuraminidase inhibitor-resistant influenza A viruses

Tatiana Baranovich et al. Curr Opin Virol. 2011 Dec.

Abstract

Antiviral drugs are important components for the control of influenza. The key question is whether antiviral use or natural virus evolution will lead to the emergence of drug-resistant virus with comparable or superior fitness to drug-susceptible counterpart. Currently, neuraminidase (NA) inhibitors (NAIs) are the first choice for influenza prevention and treatment. In this article we will review complex process of the risk assessment for the fitness of NAIs-resistant seasonal H1N1 and H3N2, pandemic 2009 H1N1, and highly pathogenic H5N1 influenza A viruses: identification of antiviral susceptibility, degree of functional NA loss, molecular markers of resistance, and evaluation of replicative ability in vivo, virulence and transmissibility in animal studies (mouse, ferret, and guinea pig models).

PubMed Disclaimer

Figures

Figure 1
Figure 1. Assessment of fitness of neuraminidase inhibitor-resistant influenza viruses in vitro and in vivo
NA, neuraminidase; WT, wild-type virus; R, NAI–resistant virus. These figures are just examples of experimental data obtained with WT and R viruses. WT=R, fitness of the wild-type virus is similar to that of its NAI-resistant counterpart; WT>R, fitness of the wild-type virus is greater than that of its NAI-resistant counterpart, data representing superior fitness of NAI-resistant counterpart as compared to wild-type virus (WT
See this image and copyright information in PMC

References

    1. Das K, Aramini JM, Ma LC, Krug RM, Arnold E. Structures of influenza A proteins and insights into antiviral drug targets. Nat Struct Mol Biol. 2010;17:530–538. A comprehensive analysis of the crystal structures of influenza A virus proteins and a description of the mechanisms of action of currently available anti-influenza drugs are given together with allosteric explanations of the drug-resistance mechanisms. Protein structure-based discovery approaches for novel anti-influenza drugs are discussed. - PMC - PubMed
    1. Meijer A, Lackenby A, Hungnes O, Lina B, van-der-Werf S, Schweiger B, Opp M, Paget J, van-de-Kassteele J, Hay A, Zambon M. Oseltamivir-resistant influenza virus A (H1H1), Europe, 2007–08 season. Emerg Infect Dis. 2009;15:552–560. - PMC - PubMed
    1. Deyde VM, Xu X, Bright RA, Shaw M, Smith CB, Zhang Y, Shu Y, Gubareva LV, Cox NJ, Klimov AI. Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J Infect Dis. 2007;196:249–257. - PubMed
    1. Dharan NJ, Gubareva LV, Meyer JJ, Okomo-Adhiambo M, McClinton RC, Marshall SA, St George K, Epperson S, Brammer L, Klimov AI, et al. Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA. 2009;301:1034–1041. - PubMed
    1. Ferraris O, Lina B. Mutations of neuraminidase implicated in neuraminidase inhibitors resistance. J Clin Virol. 2008;41:13–19. - PubMed

Publication types

MeSH terms